4-[1,1-Dimethylethyl]-2-phenylmorpholine | 23222-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-[1,1-Dimethylethyl]-2-phenylmorpholine
• 英文别名: 4-tert-butyl-2-phenylmorpholine
• CAS: 23222-63-1
• 化学式: C₁₄H₂₁NO
• 分子量: 219.327
• InChiKey: YAOKPRXVGSXSND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-[1,1-dimethylethyl]-5-oxo-2-phenylmorpholine 、 dimethyl sulfide borane 在 silica 、 二氯甲烷 作用下， 生成 4-[1,1-Dimethylethyl]-2-phenylmorpholine
  参考文献：
  名称：

  Morpholine compounds

  摘要：

  一种增加家畜体重、改善饲料利用效率、增加瘦体重、降低出生死亡率和增加出生后存活率的方法，包括向家畜投与化合物(I)或其兽医可接受的酸加成盐的有效、非毒性剂量：##STR1## 其中R1是苯基(C1-6)烷基或可选地取代的C1-6烷基，W是可选地取代的苯基、杂环基或在苯基上可选地取代的苯氧甲基。公式(I)的某些化合物是新颖的。

  公开号：

  US04914202A1

文献信息

• P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
  申请人：Burgey Christopher S

  公开号：US20100266714A1

  公开（公告）日：2010-10-21

  The subject invention relates to novel P2X 3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X 3 receptor subunit modulator.

  本发明涉及一种新型的P2X3受体拮抗剂，它在治疗与疼痛有关的疾病状态中发挥关键作用，特别是可以使用P2X3受体亚单位调节剂治疗的外周疼痛、炎性疼痛或组织损伤疼痛。
• Morpholine derivatives and their use
  申请人：BEECHAM GROUP PLC

  公开号：EP0290122B1

  公开（公告）日：1992-12-23
• HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
  申请人：ARAXES PHARMA LLC

  公开号：US20210317127A1

  公开（公告）日：2021-10-14

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R 1 , L 1 , L 2 , L 3 , A 1 , A 2 , A 3 , A 4 , G 1 , G 2 , E, W, X, Y, Z, m, and n are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
• 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS
  申请人：ARAXES PHARMA LLC

  公开号：US20210380595A1

  公开（公告）日：2021-12-09

  The present invention provides e.g. 2-(2-acryloyl-2, 6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile and e.g. 2-(2-acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds of formula (I) as inhibitors of G12C mutant KRAS protein for treating tumor metastasis. The present description discloses exemplary compounds (e.g. pages 53 to 90; table 1; compounds I-1 to I-141), pharmacological data (e.g. page 125 to 128; table 2; example 1) and synthesis thereof (e.g. pages 129 to 143; examples 2 to 7). Exemplary compounds are e.g. 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(5-methyl-1H-indazol-4-yl)-4-morpholinobenzonitrile (example 2; compound I-1) and 6-(2-acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-3-methoxy-2-(5-methyl-1H-indazol-4-yl)-4-morpholinobenzonitrile (example 7; compound I-84).
• US4914202A
  申请人：——

  公开号：US4914202A

  公开（公告）日：1990-04-03